CBC Biotechnologies Inc , CBCBio a global leader in the use of synthetic biology to create pharmaceutical grade cannabinoids announced today it has completed its 7 million Series A funding round led by Tuatara Capital a New York – based private equity fund focused on investments in cannabis related companies A driver for this investment is CBCBio’s proprietary methods which enable production of biocatalyzed cannabinoids that are rapidly produced purer in form have a greatly reduced environmental impact and are more cost effective than what is currently available in the marketplace
CBCBio is a biopharmaceutical company focused on the production of cannabinoids and discovery development and commercialization of cannabinoid-based therapeutics for significant unmet medical needs across the globe
Tuatara has been actively searching for the premier business in cannabinoid research and development and what we have found in CBCBio exceeds all expectations said Robert Hunt Partner Tuatara Capital The patent suite that CBCBio possesses in this space puts them squarely in the lead position ‘
As a global leader in the use of synthetic biology to create pharmaceutical grade cannabinoids our technology enables opportunities that no other method has been able to achieve said Jeffrey Korentur CBCBio’s President and CEO Our cutting edge technologies and market solutions represent a pioneering leap forward from current formulation plant extraction and chemical synthesis methods of production We are pleased to partner with a market leader like Tuatara to help realize the future in pharmaceutical grade cannabinoids ‘
CBCBio is scaling its proprietary methods for biocatalytic production of cannabinoids to produce large quantities of THC CBD CBC and other compounds says Dr Richard Peet Executive Vice President of CBCBio
Tuatara’s substantial funding further enables CBCBio’s commitment to delivering cost effective pharmaceutically pure cannabinoids in support of medical research product development and implementation
Our partnership with Tuatara ensures our ability to bring CBCBio’s proprietary technology to market and realize our position as the vanguard of cannabinoid sciences stated Christopher Brink Co-Founder and Director of CBCBio
About CBC Biotechnologies Inc
CBC Biotechnologies Inc CBCBio is an international biopharmaceutical company focused on the use of synthetic biology and advanced formulation for the production and implementation of cannabinoid based therapies With U S headquarters in Tampa Florida CBCBio manufactures and licenses technology to make cost effective pharmaceutically pure cannabinoids as an industry leader in support of advancing medical research and product development CBCBio’s global technology and intellectual property represent a breakthrough in the creation and delivery of cannabinoid based medicines For more information please visit www cbcbiotech com
About Tuatara Capital L P
Tuatara Capital L P is a specialized alternative investment manager that focuses exclusively on the legal cannabis industry Tuatara makes investments throughout the supply chain from genetics through consumer consumption For more information please visit www tuataracapital com
Please note that this piece of work originally appeared in English at https://www.vcnewsdaily.com/CBC%20Biotechnologies/venture-funding.php. As Investocracy aims to bring global startup news and updates in both English and Japanese to you, it’s important that we attribute original source to you. If you have any questions/concerns please write to us at contact@investocracy.co
